Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease-Reference-Cited by-同舟云学术

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease

Published:2012 Issue:1 Volume:11 Page:60
ISSN:1475-2840
Container-title:Cardiovascular Diabetology
language:en
Short-container-title:Cardiovasc Diabetol

Author:

Klempfner Robert,Leor Jonathan,Tenenbaum Alexander,Fisman Enrique Z,Goldenberg Ilan

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Reference25 articles.

1. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study

2. Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse

3. Severe Hypoglycemia and Risks of Vascular Events and Death

4. Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

5. Vildagliptin

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease;Pharmaceutics;2023-07-01

2. Chemical synthesis of oligosaccharides and their application in new drug research;European Journal of Medicinal Chemistry;2023-03

3. Effects of citronellol grafted chitosan oligosaccharide derivatives on regulating anti-inflammatory activity;Carbohydrate Polymers;2021-06

4. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study;British Journal of Clinical Pharmacology;2019-04-13

5. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study;Cardiovascular Diabetology;2017-05-22